.svg){kind=small}
Jul-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Where to Buy
Vireo is stocked at 98 licensed dispensaries across New York and Maryland, 97 of them in New York, with the deepest coverage in New York, Rochester, Buffalo, East Syracuse, and Queens. Search by ZIP code or city below to find the closest one, or filter by product type if you are after a specific format.
Market Insights Snapshot
Vireo concentrated its July 2026 revenue in Concentrates at 95.44% share while Topical held 4.56% share, a mix that pairs a 609.54% year-over-year surge in Concentrates with a 25.09% decline in Topical, and month-over-month movement of -1.07% in Concentrates against +21.90% in Topical. Despite brand sales down 8.75% year over year and an average price up 107.52% to $44.68, Concentrates still anchors the portfolio while Topical’s rebound is incremental, implying pricing power is concentrated in a single pillar and short-term growth relies on stabilizing Concentrates while nurturing Topical’s MoM momentum.
With Concentrates ranked 20th in New York and holding 95.44% of mix alongside a -1.07% MoM dip, the brand’s position is vulnerable to category-specific shocks even as Topical’s +21.90% MoM lift provides a hedge; the +609.54% YoY gain in Concentrates versus -25.09% YoY in Topical indicates a barbell where one side delivers scale and the other offers volatility dampening. The implication is to maintain a Concentrates-led stance in New York while diversifying risk by converting Topical’s MoM momentum into sustained share growth, because the 107.52% jump in average price alongside an 8.75% YoY sales decline suggests demand elasticity that could erode rank if mix remains this concentrated.
Competitive Landscape
Vireo sits at rank #20 in New York Concentrates in July 2026 after climbing 16 positions from #36 year over year, and it improved 14 ranks from #34 three months ago to #20 while also briefly peaking at #15 in June 2026; meanwhile, UMAMII surged from #27 to #3 with 1,736.3% year-over-year sales growth and Jetpacks advanced from #3 to #2 on 56.8% growth, indicating Vireo’s upward rank trajectory is real but slower than top movers and implies a transition from mid-pack volatility toward stable competitiveness rather than leadership.
Notable Products
CBD/THC 1:1 Green Balm (50mg CBD, 50mg THC, 1.5oz) posted the largest month-over-month gain at +53.4% and climbed to rank 5, while CBD/THC 1:1 Green Balm (15mg CBD, 15mg THC, 1.5oz) plunged -59.2% to rank 6, indicating demand consolidation toward the mid-strength SKU. Indica RSO Syringe (1g) rose +32.6% to rank 1 while Hybrid RSO Syringe (1g) fell -43.6% to rank 3, and together with Sativa RSO Syringe (1g) at rank 2 this places three Concentrates in the top three slots, concentrating share in RSO formats over topicals. With Concentrates holding ranks 1–3 and Topicals clustered at ranks 4–6, the mix points to a pivot toward high-THC RSO convenience with a secondary niche in targeted balms, implying near-term prioritization of syringe availability and a single hero topical rather than a broad balm lineup.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
